This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b data If approved, ecopipam would be the first new treatment option indicated for pediatric patients with Tourette syndrome in more than 10 years and […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 6 minutes later, on .
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (none), United States (37), FDA Accepts Teva's (none), Drug Application NDA (none), Grants Priority Review (none), First-in-Class Investigational Therapy (none), Pediatric Patients (none), Tourette Syndrome (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.